<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01006720</url>
  </required_header>
  <id_info>
    <org_study_id>SUNDRO20</org_study_id>
    <secondary_id>EudraCT number 2009-013499-29</secondary_id>
    <nct_id>NCT01006720</nct_id>
  </id_info>
  <brief_title>Sugammadex and Neostigmine at Residual Neuromuscular Blockade</brief_title>
  <acronym>SUNDRO20</acronym>
  <official_title>Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare recovery times after reversal of a residual neuromuscular
      block (TOF-ratio 0.2) with different doses of either neostigmine or sugammadex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Muscle relaxants are integral part of modern anesthesia. They optimize intubating conditions,
      reduce laryngeal trauma and improve operating conditions. Drawback is a possible
      pharmacological (muscle relaxing) effect of these drugs beyond the end of the operation (i.e.
      post-operative residual curarization: PORC). Reportedly about 30% of all patients who
      received muscle relaxants show signs of PORC when arriving in the post-anesthesia care unit.
      PORC comprises the risk of impaired post-operative fine motor and coordinative skills with a
      possible impairment of swallowing pharyngeal secretions with an increased risk of aspiration
      after extubation. Possible deleterious effects of this could be pneumonia, bronchitis,
      myocardial infarction, cardiac insufficiency, stroke or re-operation.

      In order to avoid PORC patients with residual neuromuscular block receive a muscle relaxant
      antagonist from the anesthesiologist at the end of the operation. However, these drugs
      (neostigmine, pyridostigmine, etc.) from the class of cholinesterase inhibitors have unwanted
      effects such as bradycardia, increased gastro-intestinal motility, post-operative nausea and
      vomiting, salivation etc. To decrease these unwanted side effects cholinesterase inhibitors
      have to be given in combination with parasympatholyics e.g. atropine or glycopyrrolate with
      their own spectrum of unwanted side effects.

      From October 2008 on, Sugammadex, a completely new reversal drug was introduced in to
      clinical practice. Sugammadex, is a modified γ-cyclodextrine able to specifically bind
      rocuronium (a steroidal muscle relaxant). The complex is eliminated via the kidneys. However,
      all studies so far have focussed on reversal of profound or deep neuromuscular blockade. This
      study is designed to compare recovery times after reversal of a residual neuromuscular block
      (TOF-ratio 0.2) with different doses of either the neostigmine or sugammadex.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to TOF-ratio 0.9 following the investigational drug</measure>
    <time_frame>Regular anesthesia time, approximately 1.5 hours</time_frame>
  </primary_outcome>
  <number_of_groups>11</number_of_groups>
  <enrollment type="Actual">99</enrollment>
  <condition>Residual Neuromuscular Block (TOF-ratio of 0.2)</condition>
  <arm_group>
    <arm_group_label>Sgx 0.25</arm_group_label>
    <description>Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sgx 0.5</arm_group_label>
    <description>Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sgx 0.75</arm_group_label>
    <description>Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sgx 1.0</arm_group_label>
    <description>Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sgx 1.25</arm_group_label>
    <description>Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neo 10</arm_group_label>
    <description>Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neo 25</arm_group_label>
    <description>Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neo 40</arm_group_label>
    <description>Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neo 55</arm_group_label>
    <description>Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neo 70</arm_group_label>
    <description>Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <description>Saline group: Saline as placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Single intravenous injection of either:
Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)</description>
    <arm_group_label>Sgx 0.25</arm_group_label>
    <arm_group_label>Sgx 0.5</arm_group_label>
    <arm_group_label>Sgx 0.75</arm_group_label>
    <arm_group_label>Sgx 1.0</arm_group_label>
    <arm_group_label>Sgx 1.25</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)</description>
    <arm_group_label>Neo 10</arm_group_label>
    <arm_group_label>Neo 25</arm_group_label>
    <arm_group_label>Neo 40</arm_group_label>
    <arm_group_label>Neo 55</arm_group_label>
    <arm_group_label>Neo 70</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline 0.9% (Saline)</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving rocuronium for neuromuscular blockade under general anesthesia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ASA physical status I - III

          -  Patients over 18 years

          -  Patients scheduled for general anesthesia with intubation using rocuronium

          -  Patients having given informed consent to the study

        Exclusion Criteria:

          -  Anatomic and functional malformations with expected difficult intubation

          -  Known or suspected neuromuscular disease

          -  Significant hepatic or renal dysfunction

          -  Known or suspected history or family history of disposition to malignant hyperthermia

          -  Known or suspected allergy towards sugammadex, anesthetics, muscle relaxants, or other
             drugs used for general anesthesia

          -  Use of drugs that interfere with muscle relaxants

          -  Patients, included in another trial within the last 30 days

          -  Patients, with legal guidant

          -  Patients with contraindication towards the use of Sugammadex, neostigmine or
             glycopyrrolate

          -  Patients, which have already participated in a sugammadex trial

          -  Pregnant women (exclusion of pregnancy: postmenopausal status, negative β- HCG screen,
             status post tubal ligation)

          -  Breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidrun Fink, PD Dr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675 München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>Munic</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008 Nov;109(5):816-24. doi: 10.1097/ALN.0b013e31818a3fee.</citation>
    <PMID>18946293</PMID>
  </reference>
  <reference>
    <citation>Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, Eikermann M, Khuenl-Brady KS. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008 Aug;109(2):188-97. doi: 10.1097/ALN.0b013e31817f5bc7.</citation>
    <PMID>18648227</PMID>
  </reference>
  <reference>
    <citation>Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, Giunta FG, Meistelman C, Prins ME. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008 May;100(5):622-30. doi: 10.1093/bja/aen037. Epub 2008 Apr 2.</citation>
    <PMID>18385265</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2009</study_first_submitted>
  <study_first_submitted_qc>November 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2009</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Residual neuromuscular block</keyword>
  <keyword>post-operative residual curarization</keyword>
  <keyword>PORC</keyword>
  <keyword>sugammadex</keyword>
  <keyword>neostigmine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

